CD19 and acute lymphoblastic leukemia: PI-103 was more effective than rapamycin in suppressing proliferation of Ph+ B-ALL leukemia cells treated with imatinib [148], both in mouse pre-B ALL and human CD19+ CD34+ Ph+ ALL cells.